当前位置: 首页 >> 检索结果
41. Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
作者: Sunil V Rao.;Michelle L O'Donoghue.;Marc Ruel.;Tanveer Rab.;Jaqueline E Tamis-Holland.;John H Alexander.;Usman Baber.;Heather Baker.;Mauricio G Cohen.;Mercedes Cruz-Ruiz.;Leslie L Davis.;James A de Lemos.;Tracy A DeWald.;Islam Y Elgendy.;Dmitriy N Feldman.;Abhinav Goyal.;Ijeoma Isiadinso.;Venu Menon.;David A Morrow.;Debabrata Mukherjee.;Elke Platz.;Susan B Promes.;Sigrid Sandner.;Yader Sandoval.;Rachel Schunder.;Binita Shah.;Jason P Stopyra.;Amy W Talbot.;Pam R Taub.;Marlene S Williams.
来源: Circulation. 2025年151卷25期e1098页 42. Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.
作者: Seth S Martin.;Aaron W Aday.;Zaid I Almarzooq.;Cheryl A M Anderson.;Pankaj Arora.;Christy L Avery.;Carissa M Baker-Smith.;Bethany Barone Gibbs.;Andrea Z Beaton.;Amelia K Boehme.;Yvonne Commodore-Mensah.;Maria E Currie.;Mitchell S V Elkind.;Kelly R Evenson.;Giuliano Generoso.;Debra G Heard.;Swapnil Hiremath.;Michelle C Johansen.;Rizwan Kalani.;Dhruv S Kazi.;Darae Ko.;Junxiu Liu.;Jared W Magnani.;Erin D Michos.;Michael E Mussolino.;Sankar D Navaneethan.;Nisha I Parikh.;Sarah M Perman.;Remy Poudel.;Mary Rezk-Hanna.;Gregory A Roth.;Nilay S Shah.;Marie-Pierre St-Onge.;Evan L Thacker.;Connie W Tsao.;Sarah M Urbut.;Harriette G C Van Spall.;Jenifer H Voeks.;Nae-Yuh Wang.;Nathan D Wong.;Sally S Wong.;Kristine Yaffe.;Latha P Palaniappan.; .
来源: Circulation. 2025年151卷25期e1095页 43. Response by Duan and Lin to Letter Regarding Article, "Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics".44. Insights Into Recovery From Acute Fulminant Myocarditis Following Successful Treatment With Ruxolitinib by Comprehensive Single-Cell Profiling.
作者: Juan Qin.;Mandar A Aras.;Evelyn J Song.;Andrew J Connolly.;Lylybell Zhou.;Connor O'Brien.;Joe-Elie Salem.;Arun Padmanabhan.;Javid J Moslehi.
来源: Circulation. 2025年151卷25期1814-1817页 45. Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy.
作者: Pernille G Thrane.;Michael Maeng.;Akiko Maehara.;Hans Erik Bøtker.;Gary S Mintz.;Lars Kjøller-Hansen.;Thomas Engstrøm.;Mitsuaki Matsumura.;Lak N Kotinkaduwa.;Ole Fröbert.;Jonas Persson.;Rune Wiseth.;Alf I Larsen.;Lisette O Jensen.;Jan E Nordrehaug.;Øyvind Bleie.;Claes Held.;Stefan K James.;Ziad A Ali.;David Erlinge.;Gregg W Stone.
来源: Circulation. 2025年151卷25期1767-1779页
Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment-elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI). Whether the prevalence of untreated high-risk vulnerable plaques differs in STEMI and NSTEMI and affects their outcomes is unknown.
47. Letter by Wang et al Regarding Article, "Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics".48. Response by Murai et al to Letter Regarding Article, "Impact of Post-PCI Lipid Core Burden Index on Angiographic and Clinical Outcomes: Insights From NIRS-IVUS".
作者: Woohyeun Kim.;Hyungdon Kook.;Yonggu Lee.;Young-Hyo Lim.
来源: Circ Cardiovasc Imaging. 2025年e018586页 52. Dynamic Updating Strategies to Assess Hospital Performance of Surgical Aortic Valve Replacement.
作者: Jackie Pollack.;Wei Yang.;George J Arnaoutakis.;Michael J Kallan.;Stephen E Kimmel.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011608页
Prediction models determining expected outcomes are infrequently updated (ie, static), which may reduce accuracy and misclassify hospital performance over time. Dynamic models incorporate changes over time and may improve accuracy and fairness in hospital comparisons. This study evaluated whether dynamic updating, compared with a static model, altered hospital rankings and outlier detection among surgical aortic valve replacement patients.
54. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
作者: Samer Al Said.;Siddharth M Patel.;Robert P Giugliano.;David A Morrow.;Erica L Goodrich.;Sabina A Murphy.;Bruce Hug.;Sanobar Parkar.;Shih-Ann Chen.;Shaun G Goodman.;Boyoung Joung.;Robert G Kiss.;Wojciech Wojakowski.;Jeffrey I Weitz.;Dan Bloomfield.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2025年
Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.
55. Response by Wang et al to Letter Regarding Article, "Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis".60. Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic Hearts.
作者: Dorothea Kehr.;Janek Salatzki.;Birgit Seger.;Karl Varadi.;Jennifer Birkenstock.;Philipp Schlegel.;Erhe Gao.;Walter J Koch.;Hugo Katus.;Norbert Frey.;Johannes Riffel.;Florian André.;Karsten Peppel.;Andreas Jungmann.;Martin Busch.;Helga Pfannkuche.;Julia Ritterhoff.;Patrick Most.
来源: Circ Heart Fail. 2025年e012479页
Guided by long-term safety data for AAV5 (adeno-associated virus 5) in humans, our translational study investigated whether AAV5 effectively delivers genes to healthy and achieves therapeutic efficacy in dysfunctional human-sized hearts, using a clinically applicable mode of administration and vector dosages.
|